Skip to content

Effect of purslane on the control of rheumatoid arthritis

Assessing the effect of purslane supplementation on clinical outcomes, inflammatory and oxidative stress markers in patients with rheumatoid arthritis: A parallel double-blinded randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120415009472N25
Enrollment
86
Registered
2022-06-21
Start date
2022-07-23
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention 1: Intervention group: 43 people in the group receiving 500 mg capsules of portulaca oleracea extract from Perpin Ala-Exir Jahani Company (two per day, one after breakfast and one after d

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of Rheumatoid Arthritis Based on American College of Rheumatology (ACR) Criteria(If there are at least four criteria for six weeks of the criteria 1- Morning dryness for at least one hour in three joints or more 2- Arthritis of three joint areas or more 3- Arthritis of the hand joints 4- Symmetric arthritis 5- Rheumatoid nodules 6- Positive rheumatoid factor 7- Typical radiographic changes in the wrist and hand) The duration of the disease is at least one year The patient expresses his / her consent to participate in the study

Exclusion criteria

Exclusion criteria: Having any of the diseases of diabetes, hypertension, thyroid disorder and kidney failure and Liver dysfunction Smoking Taking supplements (omega 3, antioxidants, etc.) in the last three months Taking contraceptives Changes in the amount of medication taken in the past month Patients who have followed a specific diet in the last three months Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
High-Sensitivity C-Reactive Protein (hs-CRP). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Tumour necrosis factor- a(TNF-a). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Total antioxidant capacity (TAC). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Chromatography.;Erythrocyte sedimentation rate(ESR). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Vacuum tube erythrocyte sedimentation rate.;Superoxide dismutase(SOD). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Spectrophotometry.;Tender joint counts (TJC). Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Doctor checkup.;Swollen joint count. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Doctor checkup.;Illness severity. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Physician global assessment.;Pain. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Visual analogue scale.;Disease activity score. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Formula DAS28.;Morning stiffness. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: How long (minutes) it takes for the joint dryness to go away.;Number of painful joints. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Doctor checkup.;Telopeptide C. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Osteocalcin. Timepoi

Secondary

MeasureTime frame
Dosage of non-steroidal anti-inflammatory drugs. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Questionnaire.;BMI. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Formula.;Waist. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Tape meter.;Blood pressure. Timepoint: Before the intervention and after the end of the intervention. Method of measurement: Manometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaheed Aryaeian

Iran University of Medical Sciences

n-aryaeian@sina.tums.ac.ir+98 21 8670 4750

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026